cmAngio® vs ASSURE Wearable ECG
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your objective is to enhance cardiovascular risk assessment in women by leveraging existing mammography data. This AI-powered solution provides non-invasive detection and visualization of Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, offering valuable insights for early risk stratification without additional patient procedures.
View cmAngio® →Choose ASSURE Wearable ECG if…
Choose ASSURE Wearable ECG if you require continuous, real-time cardiac monitoring and data collection for at-risk patients in an outpatient setting. This wearable device, integrated with a remote patient data platform, is ideal for ongoing diagnostic surveillance, providing automatic episode storage, alert-based notifications, and physiologic trend data for proactive patient management.
View ASSURE Wearable ECG →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | ASSURE Wearable ECG |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | The ASSURE system is intended for use by a patient during their normal daily activities primarily in the home or community setting, but also hospitals, medical clinics, healthcare facilities and transport. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngiou00ae integrates directly into existing radiology workflows with quick installation and compatibility with any DICOM-compliant viewer, minimizing disruption for clinical staff. While ASSURE Wearable ECG focuses on patient comfort and ease of use, the software-only nature of cmAngiou00ae generally presents a lower barrier to adoption and a simpler user experience for healthcare providers.
Clinical Value
TieBoth tools offer significant and FDA-cleared clinical value in different aspects of cardiology. cmAngiou00ae provides early cardiovascular risk assessment by leveraging existing mammography data, offering a non-invasive screening method. ASSURE Wearable ECG delivers continuous, real-time heart rate monitoring for at-risk cardiac patients, enabling timely intervention and management.
Pricing & Value
cmAngio®While both products require direct contact for pricing, cmAngiou00ae explicitly mentions 'limited-time offers for no-cost implementation and service.' This suggests a potentially lower initial cost barrier or a more attractive value proposition for healthcare providers looking to adopt the technology.
Enterprise Readiness
ASSURE Wearable ECGBoth tools are FDA-cleared, HIPAA-compliant, and cloud-based, demonstrating strong foundational enterprise readiness. However, Tool B explicitly states it 'has_baa: 1' in its structured facts, indicating a confirmed Business Associate Agreement, whereas Tool A requires contacting the vendor for BAA details.
Innovation
cmAngio®cmAngiou00ae demonstrates a high degree of innovation by repurposing existing mammography data to identify Breast Arterial Calcifications for cardiovascular risk assessment, creating a novel screening pathway without additional procedures or radiation. While ASSURE Wearable ECG offers innovative wearable technology and advanced signal processing, cmAngiou00ae's approach of extracting new, critical insights from routinely collected data stands out.
Support & Docs
ASSURE Wearable ECGKestra Medical Technologies, the company behind ASSURE Wearable ECG, provides a dedicated 'Support' section on its website with resources for both patients and clinicians, indicating a structured approach to documentation and assistance. In contrast, CureMetrix's website for cmAngiou00ae offers general contact information but no readily apparent dedicated support portal or public documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | ASSURE Wearable ECG |
|---|---|---|
| Product Name | cmAngiou00ae | ASSURE Wearable ECG |
| Company | CureMetrix | Kestra Medical Technologies |
| Primary Function | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | Non-therapeutic device for continuous heart rate monitoring and data collection, integrated into their digital healthcare platform for at-risk cardiac patients. |
| Key Specific Feature | AI-based detection of Breast Arterial Calcifications (BAC) | Wearable ECG device for continuous heart rate monitoring |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and ASSURE Wearable ECG.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or ASSURE Wearable ECG
Backers
Who funded each tool's parent company.